2021 is expected to bring change to the drug pricing sphere—exactly when and how is still not entirely known. What is known is that the Biden administration has provided an agenda that includes negotiation regarding drug prices by Medicare. There are several possibilities all leading to a variety of impacts, discussed in this recent article in STAT News.
According to Ed Schoonveld of ZS Associates, “Given the impact of drug pricing controls on the future global pharmaceutical landscape, biopharmaceutical companies need to engage in robust scenario analysis to inform their milestone drug development decisions, such as the Phase 3 go/no go decisions and associated clinical trial plans.” Learn more here.
(Source: Ed Schoonveld, STAT News, 2/2/21)